Antibodies
15 February 2007
Peregrine Pharmaceuticals Reports Positive Phase Ib Results for its Targeted Immunotherapy Bavituximab in Chronic Hepatitis C Infection15 February 2007
DSM and Crucell announce breakthrough in the production of biopharmaceuticals with PER.C6(R) technology platform14 February 2007
GlaxoSmithKline and Human Genome Sciences announce initiation of Phase 3 clinical trial of Lymphostat-B(R) in systemic lupus erythematosus14 February 2007
Seattle Genetics Receives Orphan Drug Designations for its SGN-33 and SGN-35 Programs14 February 2007
Boehringer Ingelheim and Xencor Enter into Antibody License and Commercialization Agreement13 February 2007
BioInvent and ThromboGenics Receive Approval to Begin Clinical Trials for Anticoagulant TB-4028 February 2007
Biogen Idec Initiates Randomized, Registrational Trial of Lumiliximab for Chronic Lymphocytic Leukemia7 February 2007
ImClone Systems Opts-out of Development Agreement with UCB to Focus Resources on Proprietary, Anti-VEGFr-2 Antibody IMC-1121B6 February 2007
AstraZeneca Licenses Regeneron’s Velocimmune(R) Technology For Discovering Human Monoclonal Antibodies6 February 2007
UCB Licenses BioWa’s POTELLIGENT(R) Technology for use in Antibody Research and Development3 February 2007
Genentech Announces Positive Results from a Phase IV Study of Raptiva in Patients With Moderate-to-Severe Hand and Foot Psoriasis26 January 2007
Biogen Idec Initiates Phase III Trial of Galiximab for Follicular Non-Hodgkin’s Lymphoma26 January 2007
Amgen’s Fourth Quarter 2006 Revenue Increased 17% to $3.8 Billion; Full Year 2006 Revenue Increased 15% to $14.3 Billion25 January 2007
Kirin and Astellas Enter Into a Licensing Agreement on an Immunosuppressive Fully Human Monoclonal Antibody25 January 2007
First Actemra multinational phase III trial demonstrates significant improvement in signs and symptoms of rheumatoid arthritis17 January 2007
Nabi Biopharmaceuticals Announces Initiation of Civacir(R) Phase II ‘Proof-of- Concept’ Clinical Trial17 January 2007
Oxford Biomedica Announces Publication Of Avian Transgenic Results In Leading U.S. Scientific Journal16 January 2007
4- Antibody AG Closes CHF 17 Million Series A Financing, Bringing the Total Series A Financing to CHF 23 Million ($ 18.5Million)11 January 2007
Organon and the Academic Medical Center jointly develop novel treatment of rheumatoid arthritisNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports